Want to see LFCR full AI Analyst Report?
LFCR Stock Chart & Stats
$4.54
<$0.01(0.23%)
At close: 4:00 PM EDT
$4.54
<$0.01(0.23%)
Day’s Range― - ―
52-Week Range$3.63 - $8.98
Previous Close$4.34
Volume111.66K
Average Volume (3M)128.19K
Market Cap
$168.82M
Enterprise Value$386.59
Total Cash (Recent Filing)$17.47M
Total Debt (Recent Filing)$142.61M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding37,853,060
10 Day Avg. Volume107,634
30 Day Avg. Volume128,191
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)-21.64
Price to Sales (P/S)9.00
P/FCF Ratio49.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.25Price Target Upside37.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.06
Revenue Forecast (FY)$121.43M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationPositive operating and free cash flow in 2026 provides internal funding for operations and reduces immediate dependence on external capital, although the improvement still requires evidence of consistency.
Integrated CDMO OfferingThe ability to support injectable products across development, technical services, and manufacturing can deepen customer relationships and create opportunities to retain programs as they advance toward commercial supply.
Stable Gross MarginsRelative gross-margin stability indicates that the core service offering has maintained its underlying economics despite volatile earnings, providing a foundation for improvement if utilization and operating discipline strengthen.
Bears Say
Weak Capital StructureHigh leverage combined with negative equity limits financial flexibility and increases refinancing and solvency risk, potentially constraining investment in capacity, technology, and customer programs.
Persistent UnprofitabilityFlat-to-declining revenue and recurring operating losses show that the business has not yet converted its CDMO capabilities into durable profitability, leaving earnings highly sensitive to project timing and execution.
Inconsistent Cash FlowAlthough cash generation improved in 2026, the long record of inconsistent operating cash flow and the latest free-cash-flow decline weaken confidence that internally generated funds can reliably support debt service and growth.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $3.63 and its highest was $8.98 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is $168.82M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is May 12, 2027 which is in 252 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Aug 05, 2026. The company reported -$0.19 earnings per share for the quarter.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Undervalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,853,060 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -$0.19 in its last earnings report. Following the earnings report the stock price went up 9.009%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in LFCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LFCR Company Deck
LFCR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.View all LFCR earnings summariesLFCR Stock 12 Month Forecast
Average Price Target
$6.25
▲(37.67% Upside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
16.90% Insiders
6.28% Mutual Funds
45.14% Other Institutional Investors
24.39% Public Companies and
Individual Investors